Mixed Data Cloud Future Of Sunovion's ADHD Drug
Sunovion's ADHD drug, dasotraline, has missed its primary endpoint in a Phase III study in adult patients but has reported mixed results in children, prompting the company to continue pursuing its 2017 plans for an FDA filing in both age groups. But data for the non-stimulant ADHD therapy suggest it will be tricky to overthrow market stalwarts.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.